← All episodes

381‒Alzheimer’s disease in women: how hormonal transitions impact the brain, new therapies, & more

| 15 products mentioned
Watch on YouTube alzheimer's disease women's brain health menopause hormone replacement therapy estrogen receptors neuroimaging biomarkers

In this episode, Peter Attia interviews neuroscientist Lisa Mosconi about why Alzheimer's disease disproportionately affects women at roughly a 2-to-1 ratio compared to men—a disparity that cannot be explained by longevity alone. Mosconi presents evidence that women begin developing Alzheimer's pathology in midlife, particularly during the menopausal transition when estrogen levels decline sharply, and discusses how menopausal hormone therapy initiated at the right time may help reduce cognitive decline and dementia risk. The conversation covers cutting-edge brain imaging techniques, estrogen receptor biology, and Mosconi's ambitious $50 million CARE research initiative aimed at preventing Alzheimer's in women globally.

Key takeaways
  • Women show higher brain pathology burden in midlife compared to age-matched men with the same genetic risk factors, suggesting Alzheimer's disease begins decades before symptoms appear.
  • The APOE4 gene confers a 4-6 fold increased dementia risk in women versus a 2-fold increase in men, demonstrating that sex-specific genetic risk models are critical for Alzheimer's prevention.
  • Estrogen receptor density in the pituitary gland actually increases after menopause, contradicting rodent models and suggesting the "window of opportunity" for hormone therapy may extend beyond age 65.
  • Early initiation of menopausal hormone therapy (within 10 years of final menstrual period) is associated with a 23-32% reduced dementia risk in observational studies, particularly with estrogen-only therapy in hysterectomized women.
  • The blood-brain barrier actively regulates estrogen transport, meaning peripheral estrogen levels tell you almost nothing about estrogen availability in the brain or symptom severity during menopause.
  • Advanced MRI techniques including DTI, ASL, and phosphorus spectroscopy can now measure brain white matter integrity, blood flow, and neuronal energy production to identify Alzheimer's pathology years before cognitive decline.

Recommendations (7)

Logan plot uses

"There's a whole mathematical model that we're using. It's called the Logan plot."

Peter Attia · ▶ 41:10

C11 PIB uses

"We also use another tracer is called C11 PIB Pittsburgh compound B which shows Alzheimer's plaques in the brain."

Peter Attia · ▶ 34:14

FDG PET uses

"We use FDG like you mentioned that looks at metabolic activity in the brain."

Peter Attia · ▶ 34:08

"The way that this tracer works is called flurin 18 fluoroestradiol is that it goes up in the brain and it looks for the estrogen receptors."

Peter Attia · ▶ 37:37

DTI uses

"We can do DTI which is diffusion tensor imaging where you can see the structural connectivity of your brain all the different fibers that connect the different neurons."

Peter Attia · ▶ 31:41

ASL uses

"We also use a modified version of an MRI to look at blood flow with ASL, arterial spin labeling, which is completely non-invasive and is also really quick."

Peter Attia · ▶ 32:01

"We do 31P phosphor phosphorus 31 magnetic resonance spectroscopy to look at ATP production in the brain."

Peter Attia · ▶ 32:18

Mentioned (8)

Phytoerm "This specific substance leaves your reproductive organs alone but goes up into the brain and bind..." ▶ 1:31:31
UK Biobank
UK Biobank "Studies like care and other prospective cohort studies and large-scale bio repositories I think t..." ▶ 1:46:54
C2N "We could look at C2N, we could look at PAL, we could look at any of the other brain metabolomics,..." ▶ 1:44:50
PreciviTy "What do you think of the commercially available versions of PTA and these other studies?" ▶ 1:45:22
Welcome Leap "I just launched a $50 million program of research sponsored by Welcome Leap, which is an independ..." ▶ 1:10:56
Welcome Trust "I just launched a $50 million program of research sponsored by Welcome Leap, which is an independ..." ▶ 1:10:56
Tirzepatide "I have seen some unpublished data that suggest that very low like 2.5 milligrams of tirzepatide a..." ▶ 2:00:55
Lancet Commission "For those interested in Alzheimer's disease, whenever it comes to Alzheimer's prevention, we look..." ▶ 1:51:26